Fed Circuit erred in Sandoz v Amgen, says solicitor general

28-02-2017

Fed Circuit erred in Sandoz v Amgen, says solicitor general

iko636 / iStockphoto.com

The US Court of Appeals for the Federal Circuit erred in holding that biosimilar applicants must give 180 days’ pre-marketing notice after an application has been approved by the US Food and Drug Administration (FDA), according to the acting solicitor general.


Sandoz v Amgen, biologics, biosimilar, BPCIA, SCOTUS, Federal Circuit, patent dance, amicus brief

LSIPR